COPD is not a single disease but a chronic respiratory condition characterized by persistent airflow limitation, usually associated with airway inflammation, destruction of lung tissue, or both. Exercise places greater demands on the respiratory system, and many patients experience dyspnea, or the distressing sensation of difficult breathing, even during ordinary activities such as walking, bathing, or climbing stairs. During exertion, the lungs may not empty efficiently before the next breath begins, a process called dynamic hyperinflation. This can leave patients feeling that they cannot draw in enough air. Although the sensation is not always a direct sign of immediate danger, it can be interpreted by the brain as a threat, producing anxiety and encouraging avoidance.

The study by Liu, Fan, Zhou and colleagues focuses on how patients themselves experience this fear of movement. Rather than measuring kinesiophobia only through a numerical questionnaire, the researchers use a qualitative phenomenological approach, a method designed to explore how people perceive, interpret, and give meaning to events in their daily lives. Phenomenological research is particularly useful when a medical problem is shaped by emotion, memory, social expectations, and personal experience. Two patients with the same level of airflow obstruction may respond very differently to exercise: one may view breathlessness as a temporary and manageable sensation, while another may interpret it as evidence that activity is dangerous. Understanding that difference is central to designing effective care.

Kinesiophobia is often discussed in relation to chronic pain, where patients avoid movement because they fear reinjury. In COPD, the mechanism is different but follows a similar feedback loop. A patient walks, becomes breathless, and stops. The immediate relief reinforces the decision to avoid walking in the future. Over time, reduced activity leads to muscle deconditioning, meaning that the muscles become less efficient and require more oxygen for the same task. Physical exertion then produces breathlessness even sooner, confirming the patient’s original fear. This cycle can gradually shrink a person’s “activity world,” transforming short trips, household tasks, and social visits into perceived threats.

The significance of the research lies in its attention to the subjective experience behind that cycle. A clinical record may show reduced exercise capacity, low daily step counts, or poor performance on a walking test, but those measurements cannot fully explain why a patient avoids activity. Fear may be linked to a previous hospitalization, a frightening episode of breathlessness, a belief that oxygen levels will suddenly collapse, or concern about appearing weak in public. Some patients may also avoid exercise because they feel that healthcare professionals expect too much from them. Others may have learned, through repeated episodes of distress, to treat any increase in breathing effort as a warning signal.

These perceptions matter because pulmonary rehabilitation is one of the most effective non-drug interventions for COPD. Carefully supervised exercise can improve muscle efficiency, endurance, functional capacity, and quality of life, even when the underlying obstruction in the airways remains. Rehabilitation programs commonly combine aerobic activity, strength training, breathing strategies, education, and psychological support. Yet attendance and long-term adherence can be difficult. If a patient believes that breathlessness means immediate physical harm, instructions to “exercise more” may sound not encouraging but unsafe. The study’s phenomenological perspective highlights why rehabilitation must address the meaning of symptoms, not simply prescribe a target duration or intensity.

Technically, safe rehabilitation depends on the distinction between expected exertional symptoms and medical danger. Exercise can increase respiratory rate, heart rate, and perceived breathlessness without causing tissue damage. Clinicians can monitor oxygen saturation, heart rhythm, symptoms, and recovery time while gradually increasing workload. Pursed-lip breathing, pacing, interval exercise, and controlled rest periods may help reduce the sensation of air trapping. Education can also change how patients interpret bodily signals. When individuals understand that breathlessness can be uncomfortable yet manageable under supervision, the alarm response may become less intense. However, reassurance alone is not enough. It must be paired with individualized assessment, because COPD varies widely and some symptoms do require urgent evaluation.

The study also points toward a broader view of COPD as a condition involving the brain, body, and environment. Fear is not merely an attitude that patients can discard through willpower. It can be strengthened by previous emergencies, social isolation, depression, limited transportation, financial constraints, and the absence of safe places to exercise. Family members may unintentionally reinforce inactivity by discouraging patients from doing more. Conversely, supportive relatives, respiratory therapists, physiotherapists, and peer groups can make movement feel predictable and achievable. A person’s confidence may rise when exercise is introduced in small steps and progress is measured by meaningful goals, such as reaching the kitchen, visiting a shop, or playing with grandchildren.

Because this is a qualitative phenomenological investigation, its value is not primarily in producing a universal numerical estimate of how common kinesiophobia is. Instead, it can reveal patterns of thought and experience that conventional clinical scales may miss. Such insights can guide the development of better questionnaires, interview tools, and rehabilitation protocols. They may also encourage clinicians to ask direct questions: What do you fear will happen when you become breathless? Which activities do you avoid? Have you ever stopped exercising because you thought you were harming your lungs? Answers to these questions could identify patients who need graded exposure to activity, psychological counseling, more detailed education, or closer supervision during rehabilitation.

The message emerging from this research is both cautionary and hopeful. For people living with COPD, fear of movement can become an invisible form of disability, narrowing daily life long before physical capacity is completely lost. But fear is also a modifiable target. By combining respiratory medicine, physiotherapy, behavioral science, and compassionate communication, healthcare teams may be able to interrupt the cycle of breathlessness, anxiety, avoidance, and deconditioning. The new study brings attention to the lived reality behind a familiar clinical problem: sometimes the first step toward better breathing is helping patients feel safe enough to move.

Subject of Research: Kinesiophobia and the lived experiences of patients with chronic obstructive pulmonary disease

Article Title: Experiences of kinesiophobia in patients with chronic obstructive pulmonary disease: a qualitative phenomenological study

Article References: Liu, X., Fan, W., Zhou, T. et al. “Experiences of kinesiophobia in patients with chronic obstructive pulmonary disease: a qualitative phenomenological study.” Scientific Reports (2026). https://doi.org/10.1038/s41598-026-66659-y

Image Credits: AI Generated

DOI: 10.1038/s41598-026-66659-y

Keywords: chronic obstructive pulmonary disease, COPD, kinesiophobia, fear of movement, dyspnea, pulmonary rehabilitation, qualitative research, phenomenology, exercise avoidance, respiratory health

COPD remains a significant global health challenge, characterized by persistent respiratory symptoms and airflow limitation. It is primarily caused by significant exposure to noxious particles or gases, with smoking being the most prevalent risk factor. The pathophysiology of COPD involves a complex interplay between inflammation, oxidative stress, and subsequent remodeling of lung tissue. As COPD progresses, patients often experience exacerbations that can lead to further deterioration in lung function and quality of life. Therefore, effective management strategies are essential for improving outcomes.

One of the key aspects of the ORESTES study was its focus on a combination therapy involving Budesonide, Glycopyrronium, and Formoterol Fumarate Dehydrate. This triple therapy is designed to target multiple aspects of the disease pathology simultaneously. Budesonide, a corticosteroid, aims to reduce inflammation, while Glycopyrronium and Formoterol are long-acting bronchodilators that relieve bronchospasm and improve airflow. This combination not only addresses the respiratory symptoms but also aims to enhance patient adherence due to the convenience of a single inhaler device, which reduces the treatment burden.

In his letter, Golpe highlights the critical importance of real-world evidence in assessing the effectiveness and feasibility of COPD treatments. While randomized controlled trials provide robust data, they often represent a highly controlled environment that may not accurately reflect clinical practice. The ORESTES study’s real-world design enables a closer examination of how treatments perform in everyday scenarios, capturing variability in patient populations, comorbidities, and adherence patterns. This information is invaluable for clinicians aiming to personalize treatment for individuals living with COPD.

Golpe also addresses the necessity for considering patient-reported outcomes alongside clinical metrics. COPD can significantly impact a patient’s quality of life, contributing to physical and emotional limitations. Therefore, understanding how treatments influence day-to-day activities, symptom burden, and overall well-being is paramount. The ORESTES study incorporated elements of patient-reported outcomes, making its findings particularly salient for clinicians focused on patient-centered care.

Moreover, the letter discusses the potential implications of socioeconomic factors on treatment outcomes. Patients from diverse backgrounds may experience disparate access to healthcare resources, support systems, and education about their condition. For example, in certain regions of Spain, the availability of healthcare professionals specialized in respiratory diseases might vary, affecting the management of COPD. Golpe’s commentary emphasizes the need for healthcare policymakers to ensure equitable access to COPD therapies and education across all patient demographics.

Treatment adherence is another focal point in Golpe’s letter. The transition to real-world studies has illuminated the challenges of medication adherence among patients with chronic conditions. Despite the benefits of combination inhalers, patients may struggle with adhering to prescribed regimens due to factors like complex dosing schedules or side effects. Therefore, Golpe advocates for healthcare providers to engage in ongoing communication with patients, fostering an environment where individuals feel empowered to discuss challenges openly.

The role of patient education cannot be understated in managing chronic diseases like COPD. Golpe’s reflections underscore that simply providing medication is insufficient; healthcare providers must also equip patients with the knowledge required to manage their condition effectively. This includes understanding how to use inhalers correctly, recognizing exacerbation symptoms, and knowing when to seek medical advice. Empowered patients are more likely to adhere to treatment and engage actively in their healthcare journey.

As the healthcare community continues to build upon the findings of the ORESTES study, ongoing research will be critical. Future studies should aim to compare the efficacy of combination therapies across diverse populations, exploring not just pharmacological outcomes but also lifestyle modifications and their impact on overall health. Understanding the interrelationship between medication adherence, lifestyle factors, and disease outcomes will further enhance the management of COPD.

In conclusion, Golpe’s letter to the editor serves as a call to action for the medical community to consider the breadth of factors impacting COPD management. The insights derived from the ORESTES study provide a launching pad for further discussions about the complexities surrounding treatment in real-world settings. As we move forward, it is imperative to embrace a holistic approach that transcends traditional metrics and actively involves patients in their treatment pathways.

The implications of these discussions extend beyond Spain, reverberating throughout the global healthcare landscape as clinicians and researchers collaborate to refine COPD management strategies. By tackling the multifaceted challenges associated with this chronic disease, the medical community can pave the way for improved outcomes and a better quality of life for individuals living with COPD.

As research continues to evolve in this field, the insights gained from real-world studies like ORESTES will be increasingly relevant. Continued discourse, such as that encouraged by Golpe’s letter, is essential in ensuring that evolving treatment paradigms remain patient-centered, evidence-based, and adaptable to the diverse needs of individuals afflicted by chronic respiratory conditions.

Strong partnerships among healthcare professionals, patients, and policymakers will be vital in fostering a comprehensive approach to COPD management. The challenges presented by this disease are immense, yet through research, education, and collaboration, there is potential for significant advancements in care.

In order to capitalize on these advancements, it is essential to synthesize the findings of studies and encapsulate them into actionable strategies. By keeping the lines of communication open and prioritizing patient engagement, the healthcare sector can facilitate a culture of adherence and support, ultimately leading to more favorable health outcomes for individuals grappling with COPD.

Through ongoing dialogue, the medical community will not only enhance the clinical landscape but also uplift the lives of patients across the globe, ensuring that they receive the best possible care throughout their journey with COPD.

Subject of Research: Chronic Obstructive Pulmonary Disease (COPD) Management

Article Title: Letter to the Editor Regarding “Real-World Outcomes in Patients with COPD Initiating Budesonide/Glycopyrronium/Formoterol Fumarate Dehydrate in Spain: ORESTES Study”

Article References:

Golpe, R. Letter to the Editor Regarding “Real-World Outcomes in Patients with COPD Initiating Budesonide/Glycopyrronium/Formoterol Fumarate Dehydrate in Spain: ORESTES Study”.
Adv Ther (2026). https://doi.org/10.1007/s12325-026-03492-9

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s12325-026-03492-9

Keywords: COPD, Budesonide, Glycopyrronium, Formoterol Fumarate Dehydrate, ORESTES Study, real-world evidence, treatment adherence, patient outcomes, healthcare disparities.